Durvalumab: Phase I started

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565, Tokyo, Japan) said AstraZeneca began an

Read the full 163 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE